クローン病(地方腸炎)治療薬の世界市場:治験レビュー

◆英語タイトル:Crohn's Disease (Regional Enteritis) Global Clinical Trials Review, H2, 2019
◆商品コード:GDT20FB0031
◆発行会社(リサーチ会社):GlobalData
◆発行日:2019年12月
◆ページ数:901
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD5,000 ⇒換算¥540,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD7,500 ⇒換算¥810,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Crohn’s Disease (Regional Enteritis) Global Clinical Trials Review, H2, 2019
Summary

GlobalData’s clinical trial report, “Crohn’s Disease (Regional Enteritis) Global Clinical Trials Review, H2, 2019″ provides an overview of Crohn’s Disease (Regional Enteritis) clinical trials scenario. This report provides top line data relating to the clinical trials on Crohn’s Disease (Regional Enteritis). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

【レポートの目次】

Table of Contents
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Five Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by G7 Countries: Proportion of Crohn’s Disease (Regional Enteritis) to Gastrointestinal Clinical Trials 17
Clinical Trials by Phase in G7 Countries 19
Clinical Trials in G7 Countries by Trial Status 20
Clinical Trials by E7 Countries: Proportion of Crohn’s Disease (Regional Enteritis) to Gastrointestinal Clinical Trials 22
Clinical Trials by Phase in E7 Countries 24
Clinical Trials in E7 Countries by Trial Status 25
Clinical Trials by Phase 26
In Progress Trials by Phase 28
Clinical Trials by Trial Status 29
Clinical Trials by End Point Status 31
Subjects Recruited Over a Period of Time 32
Clinical Trials by Sponsor Type 33
Prominent Sponsors 34
Top Companies Participating in Crohn’s Disease (Regional Enteritis) Therapeutics Clinical Trials 36
Prominent Drugs 38
Latest Clinical Trials News on Crohn’s Disease (Regional Enteritis) 39
Nov 22, 2019: Abivax to expand Phase IIb ulcerative colitis trial to France 39
Nov 06, 2019: Protagonist Therapeutics announces first patient dosed in a phase 2 study of oral IL-23 receptor antagonist PTG-200 (JNJ-67864238) in the treatment of Crohn’s Disease 39
Oct 28, 2019: Formycon announces start of phase I clinical trial with Ustekinumab Biosimilar candidate FYB202 39
Oct 28, 2019: RedHill Biopharma to Present New Phase 3 Data on RHB-104 at the American College of Gastroenterology 2019 Annual Meeting 40
Oct 23, 2019: Provention Bio reports mixed results from Crohn’s disease study 40
Oct 21, 2019: Retrospective real-world comparative analysis highlights safety of vedolizumab and Anti-TNFa therapies in biologic-naïve patients with Ulcerative Colitis or Crohn’s Disease 40
Oct 21, 2019: Biogen and Samsung Bioepis to present data for Adalimumab biosimilar at United European Gastroenterology Week 41
Oct 17, 2019: NeuClone announces first human dose of Stelara (Ustekinumab) Biosimilar candidate in phase I clinical trial 42
Oct 11, 2019: RedHill Biopharma announces full results from positive MAP US phase 3 study and supportive top-line results from MAP US2 open-label extension study with RHB-104 in Crohn’s Disease 42
Sep 27, 2019: Takeda reports further results from VARSITY ulcerative colitis study 43
Clinical Trial Profile Snapshots 44
Appendix 938
Abbreviations 938
Definitions 938
Research Methodology 939
Secondary Research 939
About GlobalData 940
Contact Us 940
Source 941

List of Tables
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Region, 2019* 8
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 10
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019* 12
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Europe, Top Five Countries, 2019* 13
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, North America, Top Countries, 2019* 14
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2019* 15
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2019* 16
Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials, G7 Countries (%), 2019* 18
Crohn's Disease (Regional Enteritis) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19
Crohn's Disease (Regional Enteritis) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 21
Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials, E7 Countries (%), 2019* 23
Crohn's Disease (Regional Enteritis) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 24
Crohn's Disease (Regional Enteritis) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 26
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Phase, 2019* 27
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials In Progress by Phase 2019* 28
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 30
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 31
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 32
Crohn's Disease (Regional Enteritis) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019* 33
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 35
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 37
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 38

List of Figures
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Region (%), 2019* 8
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019* 12
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019* 13
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, North America, Top Countries (%), 2019* 14
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2019* 15
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2019* 16
Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials, G7 Countries (%), 2019* 17
Crohn's Disease (Regional Enteritis) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19
Crohn's Disease (Regional Enteritis) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 20
Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials, E7 Countries (%), 2019* 22
Crohn's Disease (Regional Enteritis) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 24
Crohn's Disease (Regional Enteritis) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 25
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Phase (%), 2019* 26
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials In Progress by Phase, 2019* 28
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 29
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 31
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 32
Crohn's Disease (Regional Enteritis) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019* 33
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 34
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 36
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 38
GlobalData Methodology 900

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[クローン病(地方腸炎)治療薬の世界市場:治験レビュー]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆